Tempus AI jumps on FDA clearance of AI-enabled tool to analyze cardiac MRIs
Tempus AI, a midcap medical diagnostics company that’s highlighted a push to incorporate AI technology into its products, surged on Thursday after announcing the FDA had issued a “510(k) clearance” of a new AI-enabled tool to analyze cardiac imagery from MRIs.
A 510(k) clearance — used for devices that are considered relatively low risk — essentially allows a product to be sold in the US.
While the company has never turned a profit, even on an adjusted basis, its sales are growing rapidly and the stock has had a great year, rising more than 160% in 2025.
For more on the company, check out our interview with its CEO, Eric Lefkofsky.
While the company has never turned a profit, even on an adjusted basis, its sales are growing rapidly and the stock has had a great year, rising more than 160% in 2025.
For more on the company, check out our interview with its CEO, Eric Lefkofsky.